High Content Screening Market | BioTek Instruments Inc. (U.S.), Becton, Dickinson and Company (U.S.), Bio-Rad Laboratories (U.S.), Yokogawa Electric Corporation (Japan), and Merck Millipore (U.S.).

The global high-content screening market is expected to reach USD 909.0 Million by 2022 from USD 557.1 Million in 2017, at a CAGR of 10.3%.
Danaher Corporation holds a leading position in the market. The company designs, manufactures, and markets professional, medical, industrial, and commercial products & services. Danaher Corporation primarily focuses on product launches as its key business strategy. For example, in February 2017, Molecular Devices, LLC (U.S.), a subsidiary of Danaher Corporation, launched the SpectraMax iD3 Multi-Mode Microplate Reader. This added another platform to the company’s portfolio to expand its reach in the HCS market. In April 2016, Molecular Devices, LLC (U.S.) launched the ImageXpress Micro 4 High-content Imaging System. This further strengthened the company’s HCS product portfolio.
High-content screening (HCS) is a method that is used in biological research and drug discovery to identify substances such as small molecules, peptides, or RNAi that alter the phenotype of a cell in a desired manner. High-content screening includes any method used to analyze whole cells or components of cells with a simultaneous readout of several parameters.
Becton, Dickinson and Company (BD) is one of the major players in the market. The company has a strong presence in the HCS market due to its extensive product portfolio, ranging from instruments to accessories in flow cytometry. It operates globally through a network of offices across North America, Europe, Asia-Pacific, Eastern Europe, the Middle East, and Africa. To maintain its position in the market, the company has been focusing on technological advancements in flow cytometry. In the last three years, the company has launched several products, such as the BD FACSMelody System, BD FACSymphony, BD FACSPresto system, BD FACSCelesta system, and BD FACSVia flow cytometer.
High Content Screening Market
The key strategies adopted by major players in the global high-content screening market are agreements, partnerships & collaborations, acquisitions, product launches, and geographic expansions. In this competitive market, global players aim to maintain their market position through continuous investments in R&D with a focus on developing innovative solutions or enhancing their existing solutions.
The global high-content screening (HCS) market is consolidated in nature with the top five players commanding a major share of the market. GE Healthcare (U.S.), Danaher Corporation (U.S.), PerkinElmer, Inc. (U.S.), Thermo Fisher Scientific Inc. (U.S.), and Becton, Dickinson and Company (U.S.) lead the global market. Some of the other leading players in this market include BioTek Instruments Inc. (U.S.), Bio-Rad Laboratories Inc. (U.S.), Tecan Group Ltd. (Switzerland), Yokogawa Electric Corporation (Japan), and Merck Millipore (U.S.).
Location: Dundee Rd, Illinois, USA

Comments

Post a Comment

Popular posts from this blog

Key Players in the Pyrogen Testing Market Focus on Partnerships, Agreements, & Collaborations, Acquisitions, New Product launches, and Expansions

Image
The report  " Pyrogen Testing Market  by Product (Instruments, Services, Kits and Reagents), Application (Pharmaceutical & Biotechnology, Medical Devices, Other), & by Test (In Vitro, LAL, Gel Clot, Turbidimetric, Chromogenic, Rabbit) - Global Forecasts to 2021 " ,  report provides a detailed overview of the major drivers, restraints, opportunities, current market trends, and strategies impacting the global pyrogen testing market along with the estimates and forecasts of the revenue and market share analysis. Speak to Analyst @  https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=255266155 The global pyrogen testing market is valued at $462.38 million in 2014 and is expected to grow at a CAGR of 12.23%, to reach $823.14 million by 2019. Pyrogen testing is used to determine the bacterial toxins in products intended for medical or veterinary use. Rapidly growing pharmaceutical and biotechnology industries are a major growth driver for this market. Further
Read more

Non Invasive Prenatal Testing Market| Market Trends by Instruments, Consumables, Method, Application and End User

The major factors driving the growth of this market include the growing preference for non-invasive techniques over invasive methods, rising focus on reimbursement for NIPT, launch of new and advanced NIPT products, and increasing maternal age (associated with growth in the risk of chromosomal abnormalities in babies). Furthermore, untapped emerging markets are expected to offer potential growth opportunities to players operating in the NIPT market during the forecast period. The non-invasive prenatal testing (NIPT) market is expected to reach USD 2.88 billion by 2021 from USD 1.35 billion in 2016, at a CAGR of 16.4% from 2016 to 2021. The instruments segment is divided into ultrasound device, NGS systems, PCR instruments, microarrays, and other instruments. In 2016, the consumables segment accounted for the largest share of the market. The high growth in this segment is attributed to the repeated requirements of consumables as compared to instruments in NIPT. Based on application
Read more

Global Glycomics Market Players Pursue the Strategies of Product Launches, Agreements, Expansions, Acquisitions, and Collaborations

Image
The major players in this market include Agilent Technologies (U.S.), Bruker Corp. (U.S.), Danaher Corp. (U.S.), New England Biolabs (U.S.), Prozyme Inc. (U.S.), Shimadzu Corp. (Japan), Sigma-Aldrich Corp. (U.S.), Takara Bio (Japan), Thermo Fisher Scientific (U.S.), and Waters Corp. (U.S.). The glycomics market is dominated by a few major players, with the top five players accounting for a majority of the market share. The top four players for glycomics enzymes, kits, and reagents have a combined market share of about 75.2% and for glycomics instruments have a combined market share of about 76.0%. The global glycomics market is highly evolved, with multiple different product segments. An analysis of market developments between 2011 and 2014 revealed that new product launches was the most important growth strategy employed by market leaders in this period. This strategy was adopted by most players in this market, except New England Biolabs (U.S.) and Takara Bio, Inc. (Japan).
Read more